UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Purchases 83,954 Shares of Stryker Corporation $SYK

Key Points

• UBS Asset Management increased its stake in Stryker Corporation by 4.2%, acquiring an additional 83,954 shares, bringing its total holdings to over 2 million shares valued at approximately $776.9 million.
• Insider activity includes Director Ronda E. Stryker selling 200,000 shares at $376.45 each, totaling $75.29 million, which represents a 5.84% decrease in her position.
• Stryker's recent earnings report showed a net revenue of $6.02 billion for the quarter, surpassing estimates, and the company is guiding for earnings per share of 13.400-13.600 for FY 2025.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Stryker Corporation (NYSE:SYK - Free Report) by 4.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,086,960 shares of the medical technology company's stock after acquiring an additional 83,954 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.55% of Stryker worth $776,871,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Palogic Value Management L.P. raised its position in Stryker by 5.1% in the first quarter. Palogic Value Management L.P. now owns 1,067 shares of the medical technology company's stock worth $397,000 after acquiring an additional 52 shares during the period. Zurich Insurance Group Ltd FI grew its stake in Stryker by 26.0% in the 1st quarter. Zurich Insurance Group Ltd FI now owns 237,627 shares of the medical technology company's stock worth $88,457,000 after buying an additional 49,083 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of Stryker by 13.5% in the 1st quarter. Empowered Funds LLC now owns 8,678 shares of the medical technology company's stock valued at $3,230,000 after purchasing an additional 1,034 shares in the last quarter. Faithward Advisors LLC raised its holdings in Stryker by 3.8% during the 1st quarter. Faithward Advisors LLC now owns 1,864 shares of the medical technology company's stock valued at $694,000 after buying an additional 69 shares during the last quarter. Finally, MBB Public Markets I LLC bought a new stake in Stryker during the 1st quarter valued at $334,000. Institutional investors own 77.09% of the company's stock.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.20% of the company's stock.

Stryker Stock Performance

Shares of Stryker stock opened at $393.12 on Tuesday. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The company has a market capitalization of $150.29 billion, a PE ratio of 52.07, a P/E/G ratio of 2.85 and a beta of 0.93. The company has a 50-day simple moving average of $389.47 and a two-hundred day simple moving average of $379.58.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. During the same quarter in the prior year, the company posted $2.81 earnings per share. The company's revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio is currently 44.50%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Wells Fargo & Company increased their price objective on shares of Stryker from $435.00 to $445.00 and gave the stock an "overweight" rating in a research note on Friday, August 1st. Evercore ISI raised their target price on shares of Stryker from $390.00 to $415.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Needham & Company LLC increased their price objective on shares of Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a report on Friday, August 1st. Finally, Wall Street Zen raised shares of Stryker from a "hold" rating to a "buy" rating in a report on Friday, July 18th. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker presently has an average rating of "Moderate Buy" and an average target price of $430.10.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.